HGH FRAGMENT PEPTIDE (LIPOLYTIC)
AOD-9604
AOD-9604 is a synthetic fragment of human growth hormone developed as a weight-loss candidate. Its Phase 2 obesity program did not meet the ...
CATEGORY
GLP-1 & Metabolic
Semaglutide and tirzepatide have FDA-approved indications and large Phase 3 programs. Retatrutide remains investigational. Its Phase 2 trial is published, and Lilly reported positive Phase 3 obesity results in 2026, but sponsor reporting does not replace peer review or regulatory approval.
Stronger evidence in this category
Human trial or approved-indication records are available. Read each page for the exact scope and limits.
Evidence gaps
Public attention is ahead of the current human evidence or regulatory record.
Regulatory Risk
Moderate for approved drugs, high for retatrutide. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved but face compounding enforcement issues: the FDA has taken action against compounded versions. Retatrutide is not FDA-approved, is sold as a research chemical, and has received FDA warning letter attention. Social media creators discussing off-label and research-use access are being tracked by regulators.
ALL COMPOUNDS
LONGEVITY SMALL MOLECULE
Metformin
Metformin is an FDA-approved medicine for type 2 diabetes. Longevity interest comes from biological mechanisms, observational studies, and t...
MITOCHONDRIAL PEPTIDE
MOTS-c
MOTS-c is a mitochondrial-derived peptide studied in metabolism, exercise, and aging research. Mouse experiments reported metabolic effects,...
INVESTIGATIONAL ONCE-WEEKLY PEPTIDE AGONIST OF GIP, GLP-1, AND GLUCAGON RECEPTORS
Retatrutide
Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, di...
GLP-1 RECEPTOR AGONIST
Semaglutide
Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Randomized trials suppo...
DUAL GIP/GLP-1 RECEPTOR AGONIST
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound for specific FDA-approved indications. Randomized trials ...